BridgeBio Pharma, Inc. Intrinsic Value

BBIO

Choose a model

Each card values BridgeBio Pharma a different way, shown at our starting inputs. Pick one to see and change how it works.

Earnings-$2.90 a shareEarnings is negative over the last 12 months, so it cannot be projected.

Free cash flow-$1.90 a shareFree cash flow is negative over the last 12 months, so it cannot be projected.

Discounted cash flowAdvancedNeeds a year of positive free cash flow to start from, and there is none in recent years.

Set your assumptions

BridgeBio Pharma on revenue: sales per share grow and the stock trades at a normal price-to-sales multiple. For companies not yet profitable.

Years to project

Growth of revenue per share

Revenue per share; starts at its own recent growth

Exit P/S

Starts at its own median P/S over five years

Your desired return

Margin of safety

Your buy price

The expected return is measured from it; starts at today's price

How it's worked out

Today's revenue per share
Last twelve months
$4.85
Revenue in 2031
Grows 30.0% a year for 5 years
$18.02
Price in 2031
$18.02 × 15.0 P/S
$270.33
Worth today
÷ 1.10^5: your 10% a year, taken back out
$167.85
Fair value
The most you can pay and still earn 10% a year
$167.85
Buy below
Fair value minus your 25% margin of safety
$125.89

Paying $77.89 instead gives 28.3% a year. Every rule is on the methodology page.

Outcome

What your assumptions give, and the path from today's price.

Fair value

$167.85

Expected return

28.3% a year

Future price, 2031

$270.33

Buy below

$125.89

Price 54% below fair valuePrice $77.89, at your 10% return

Projection

Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.

BridgeBio Pharma (BBIO) intrinsic value and fair value

The calculator grows one of BridgeBio Pharma's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for BBIO; this is analysis, not investment advice.

Frequently asked

What is BridgeBio Pharma's (BBIO) intrinsic value?+

With Intrinsiqq's starting inputs, BridgeBio Pharma's fair value is about $167.85 a share, based on its revenue per share. That assumes revenue per share of $4.85 grows about 30.0% a year for 5 years, the stock then trades at 15.0 times revenue, and you want a 10.0% yearly return. Every input can be changed on the page; the result is a model, not a forecast.

Is BridgeBio Pharma overvalued?+

At $77.89, the price is 54% below that fair value of $167.85, and buying at today's price would return about 28.3% a year if those inputs hold. Whether that is cheap or dear depends on whether you believe the growth and the exit multiple, which is what the calculator lets you test. This is analysis from SEC filings, not investment advice.

What growth does the BridgeBio Pharma valuation assume?+

Revenue per share grows about 30.0% a year to start, its own recent growth per share (three years for a company not yet profitable, five otherwise), capped at 20%. The exit multiple starts at its own median over five years.

What is a good margin of safety for BridgeBio Pharma?+

A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $125.89. Less predictable businesses deserve a wider cushion, or a higher desired return.

More on BBIO: Overview · Quality scorecard · Dividend safety · Financials

How the market compares: US profitability statistics

Peers

Pharmaceutical Preparations · Pick stocks to compare with BBIO

CompareIntrinsic value

KNSAKiniksa Pharmaceuticals International, plc

$96.12+3.03%71

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

COLLCollegium Pharmaceutical Inc.

$23.56-0.72%98

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

Held by ETFs

BBIO is in 104 US ETFs. The largest of them, with BBIO's weight in each:

Spot a number that looks wrong? Check it in BBIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BBIO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.